Literature DB >> 1745983

Anaplastic thyroid carcinoma: risk factors and outcome.

J G Demeter1, S A De Jong, A M Lawrence, E Paloyan.   

Abstract

Anaplastic thyroid carcinoma, in contrast to well-differentiated thyroid carcinoma, has a dismal prognosis, and little progress has been made in improving survival for this disease. We reviewed our experience during a 23-year period to identify risk factors and possible methods to improve outcome. Between 1966 and 1989, 340 patients with thyroid carcinoma underwent operation. Of these, 17 (5%) were undergoing operative treatment of anaplastic or undifferentiated thyroid carcinoma. The female/male ratio was 3.5:1, and mean age at presentation was 63 years. The most common presenting symptoms included neck mass, voice change, or dysphagia. Unusual presentations included symptomatic bradycardia from compression of the vagus nerve and superior vena cava syndrome. Four patients had a history of well-differentiated thyroid carcinoma. Nine patients had been diagnosed or treated in the past for "goiter" or a neck mass, and four patients had concurrent differentiated thyroid carcinoma associated with the anaplastic tumor. Thus 13 (76%) of 17 patients had a previous thyroid disorder, benign or differentiated malignant, and eight (47%) of 17 patients had previous or concurrent differentiated thyroid carcinoma. At the time of presentation, six patients had unilateral true vocal cord paralysis. At operation, 14 patients had local extension of the tumor and four required tracheostomy. Only five of 12 patients showed response to postoperative radiation therapy. Overall median survival was 12 months, and 13 (76%) of 17 patients died. The two patients alive longer than 12 months had only small foci of anaplastic carcinoma in association with well-differentiated carcinoma. Anaplastic thyroid carcinoma is a locally and systemically aggressive disease, with long-term survival seen only in those with well-localized anaplastic tumor. The major risk factor in this series is a history of previous benign or malignant thyroid disease. Because of this, a more aggressive approach to thyroid masses may be warranted. Long-standing goiters or benign nodules should be followed carefully and considered for resection if they grow or do not respond to medical therapy, and total thyroidectomy for malignant disease may obviate the subsequent development of anaplastic carcinoma. This method of early diagnosis and resection of abnormal thyroid tissue seems to be the only method currently available to improve the nearly uniform fatality of this disease.

Entities:  

Mesh:

Year:  1991        PMID: 1745983

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  35 in total

Review 1.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Anaplastic thyroid carcinoma.

Authors:  P I Haigh
Journal:  Curr Treat Options Oncol       Date:  2000-10

Review 3.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

Review 4.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

5.  Anaplastic thyroid carcinoma mimicking thyroid abscess.

Authors:  Tze Liang Loh; Abu Bakar Zulkiflee
Journal:  AME Case Rep       Date:  2018-05-06

6.  Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.

Authors:  J Akaishi; M Onda; J Okamoto; S Miyamoto; M Nagahama; K Ito; A Yoshida; K Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-28       Impact factor: 4.553

Review 7.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

8.  Anaplastic thyroid carcinoma: a therapeutic dilemma.

Authors:  Hang-Seok Chang; Kee-Hyun Nam; Woung Youn Chung; Cheong Soo Park
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

Review 9.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

10.  A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NFkappaB activity.

Authors:  Daniela Sorriento; Alfonso Campanile; Gaetano Santulli; Eleonora Leggiero; Lucio Pastore; Bruno Trimarco; Guido Iaccarino
Journal:  Mol Cancer       Date:  2009-11-09       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.